Clinical Trials Browser

Phase 2 × bisantrene × Other hematologic neoplasm × Clear all

NCT04989335 2023-11-28

Bisantrene Combination for Resistant AML

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute